New GMP Laboratory

Launch of New GMP Oligo Manufacturing Facility

Eurofins Genomics US Expands Capabilities with New GMP Oligonucleotide Manufacturing Facility

• New building
• GMP
• Oligos
• DNA

Eurofins Genomics US is proud to announce the opening of its state-of-the-art Good Manufacturing Practice (GMP) oligonucleotide manufacturing facility. This new facility marks a significant milestone in our commitment to excellence and innovation in genomics, enhancing our ability to meet the growing demand for high-quality oligonucleotides for both research and regulated applications.

Take a Tour

 

 

Highlights

 

 

		Facility Overview The new GMP facility is designed to provide a cutting-edge environment for the production of oligonucleotides, ensuring the highest standards of quality, safety, and efficiency. One of the key features of the facility is the complete separation of Research Use Only (RUO) and GMP production streams. This separation is critical in preventing cross-contamination and ensuring compliance with stringent regulatory requirements, thereby safeguarding the integrity of our products and processes.
		Benefits of the New Facility   Enhanced Product Quality and Safety: By fully separating RUO and GMP production, the new facility ensures that oligonucleotides intended for therapeutic use are manufactured in a controlled environment that adheres to the most rigorous quality standards. This enhances the reliability and safety of our products, which is essential for clinical applications.   Regulatory Compliance: The facility is designed to meet the latest regulatory requirements which ensures that our GMP oligonucleotides are manufactured in compliance with global standards, facilitating their use in research and regulated applications worldwide.
		Capacity and Capabilities   Increased Production Capacity The expansion significantly increases our manufacturing capacity and our fleet of equipment, allowing us to meet the growing global demand for RUO and GMP-grade oligonucleotides. This increased capacity ensures that our clients receive their products on time, supporting the rapid advancement of research and development in genomics.   Streamlined Operations and Automation The facility incorporates advanced automation and process controls, which enhance production efficiency and reduce the risk of human error. This leads to consistent product quality and shorter lead times, benefiting our customers across various sectors.
		Time Lapsed Video   Construction Video of New Facility Going Up See the new building lego-up from dirt to drywall in this quick time-lapsed video showing the construction process.

Common Questions

 

What is the mailing address for the new facility

The new address is 12621 Plantside Dr. Louisville KY, 40299. It is adjacent to our current facility at 12701 Plantside Dr. Louisville KY, 40299.

What is the effective date of the change?

The effective date is September 2, 2024.

How will this impact orders and deliveries?

Our current business operations will continue without interruption during the transition. Additional equipment has been purchased as part of this expansion, which will provide enough operational redundancy to ensure continuity throughout the process.  If you have any specific concerns about your orders, please contact our customer service team at GenomicsSupport@eurofins.com.

Does this require any action from my organization?

Please update your records with our new manufacturing site address. Direct any future correspondence to our new location from the effective date.

Will this impact sequencing orders?

No. The Sanger and ONT sequencing lab will remain in the current facility. This eliminates any chance of cross contamination from amplicons, which are a natural byproduct of amplifying samples before sequencing. Sequencing customers should continue to mail their samples to the same address, no change.

Will this impact gene synthesis?

No. Gene synthesis orders will continue to be processed at our Seattle facility. No changes.

 

Quality Obsessed

At Eurofins Genomics, we recognize that your research is valuable. To ensure that the oligos synthesized at our facilities meet all the requirements of your experimental application we have streamline the production process and implemented several quality controls at different stages of the production process. The quality control checks implemented at various points during the production process are displayed below: